<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00359905</url>
  </required_header>
  <id_info>
    <org_study_id>KMD3213-IT-CL 0215</org_study_id>
    <nct_id>NCT00359905</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of Silodosin vs. Tamsulosin and Placebo in the Treatment of the Signs and Symptoms of BPH. Multicentre, Randomised, Double-Blind, Controlled Trial With an Optional Long-Term, Open-Label Extension Phase.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Recordati Industria Chimica e Farmaceutica S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Recordati Industria Chimica e Farmaceutica S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A new drug for the treatment of benign prostatic hyperplasia is compared with placebo and
      tamsulosin (a drug belonging to the same therapeutic class) for to determine if it is safe
      and effective (the first phase of the study lasts approximately 18 weeks) and then is used
      for another 9 months to determine its long-term safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-centre, double-blind, placebo and active controlled, parallel 12 week
      treatment trial in men with signs and symptoms of benign prostatic hyperplasia, followed by a
      9 month open-label phase. The following procedures are used: physical exams,
      electrocardiograms, clinical laboratory tests, vital signs, the International Prostate
      Symptom Score, maximum urine flow rate, adverse events, concomitant medications, quality of
      life and compliance. 93 centres in 11 European countries (Finland, France, Germany, Italy,
      Netherlands, Poland, Romania, Russia, Spain, Ukraine, UK) will be involved
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in baseline total score on the International Prostate Symptom Score</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in baseline obstructive subscore of the International Prostate Symptom Score;</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in baseline irritative subscore of the International Prostate Symptom Score;</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in baseline maximum urine flow rate;</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1228</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Silodosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamsulosin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silodosin</intervention_name>
    <description>8 mg daily for 12 weeks</description>
    <arm_group_label>Silodosin</arm_group_label>
    <other_name>KMD3213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>0.4 mg daily for 12 weeks</description>
    <arm_group_label>Tamsulosin</arm_group_label>
    <other_name>Omnic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males in good general health and at least 50 years of age, with symptoms of moderate
             to severe Benign Prostatic Hyperplasia

        Exclusion Criteria:

          -  Medical conditions that would confound the efficacy evaluation

          -  Medical conditions in which it would be unsafe to use an alpha-blocker

          -  Use of concomitant drugs that would confound the efficacy evaluation

          -  Use of concomitant drugs that would be unsafe with this alpha-blocker
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Re Chapple, BSc MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2006</study_first_submitted>
  <study_first_submitted_qc>August 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2006</study_first_posted>
  <last_update_submitted>February 18, 2009</last_update_submitted>
  <last_update_submitted_qc>February 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Senior Clinical Project Leader</name_title>
    <organization>Recordati Industria Chimica e Farmaceutica S.p.A.</organization>
  </responsible_party>
  <keyword>Benign prostatic hyperplasia</keyword>
  <keyword>alpha-blockers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Signs and Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Silodosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

